Lifocity, Inc. – Trademark Portfolio

Entity Type: 03

Lifocity, Inc. holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include DURT and LIFOCITY. The owner is based in Melissa, TX.

901 Sam Rayburn Highway

Melissa, TX 75454

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

DURT
DURT
Registered 2019
LIFOCITY
LIFOCITY
Registered 2019
ENVOI
ENVOI
Abandoned 2019

Trademark Classifications

Lifocity, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

35
Advertising & Business (1 filing)

Advertising; business management; business administration; office functions

Frequently Asked Questions

How many trademarks does Lifocity, Inc. have?

Lifocity, Inc. has 3 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 abandoned.

What trademark classes does Lifocity, Inc. file in?

Lifocity, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Lifocity, Inc.'s most well-known trademarks?

Lifocity, Inc.'s registered trademark portfolio includes well-known marks such as DURT and LIFOCITY. These are among 2 currently registered trademarks in the portfolio.

What is Lifocity, Inc.'s trademark registration success rate?

Lifocity, Inc. has a 67% trademark registration rate, with 2 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.